STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
Vaxcyte says its experimental pneumococcal vaccine met the primary endpoints in a Phase 3 clinical trial, positioning the biotech to compete with Pfizer and Merck in the lucrative vaccine market. The results are company-claimed, and the report does not mention any regulatory review.
AI summary · generated only from source feed metadata; consult originalSource published
Published here
views6
Original source
STAT — Biotech
Media report · consult original reporting
Read the original ↗https://www.statnews.com/2026/10/05/vaxcyte-pneumococcal-vaccine-study-pfizer-merck/Original headline
STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
AI bilingual edit · consult originalHeadlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.